

EMADOC-1700519818-2117497

European Medicines Agency decision

EMA/PE/0000240529

of 15 May 2025

on the acceptance of a modification of an agreed paediatric investigation plan for cagrilintide, semaglutide in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

EMA/PE/0000240529

of 15 May 2025

on the acceptance of a modification of an agreed paediatric investigation plan for cagrilintide, semaglutide in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0241/2022 issued on 8 July 2022,

Having regard to the application submitted by Novo Nordisk A/S on 13 December 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 March 2025, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for cagrilintide, semaglutide, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novo Nordisk A/S, Novo Alle 1, 2880 – Bagsvaerd, Denmark.

EMADOC-1700519818-1855401
Amsterdam, 28 March 2025

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA/PE/0000240529

Scope of the application

Active substance(s):

Cagrilintide / semaglutide

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of obesity

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted to the European Medicines Agency on 13 December 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0241/2022 issued on 8 July 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 27 January 2025.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of obesity

The waiver applies to:

- the paediatric population from birth to less than 8 years of age;
- solution for injection in pre-filled pen, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of obesity

2.1.1. Indication(s) targeted by the PIP

Weight management in children and adolescents from 8 years to less than 18 years.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 8 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection in pre-filled pen

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	Study 1 Dose range-finding juvenile toxicity study in C57Bl/6J mice. Study 2 Definitive juvenile toxicity study in C57Bl/6J mice.
Clinical studies	Study 3 (NN9838-4968) 68-week double-blinded, placebo and active-controlled, randomised, parallel-group, multi-national clinical study evaluating the pharmacokinetics (PK), efficacy and safety of cagrilintide / semaglutide subcutaneous use (s.c.) versus semaglutide s.c. and placebo s.c., as an adjunct to a reduced-calorie diet and

	increased physical activity in children and adolescents from 8 years to less than 18 years of age with overweight and obesity.
Extrapolation, modelling and simulation studies	Study 4 Population pharmacokinetic (pop-PK) dose-finding modelling and simulation study.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.